These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 16487234)

  • 1. Hydroxylation of lansoprazole in poor metabolizers of CYP2C19.
    Furuta T; Shirai N; Sugimoto M; Nakamura A; Hishida A
    Br J Clin Pharmacol; 2006 Mar; 61(3):361; author reply 361-2. PubMed ID: 16487234
    [No Abstract]   [Full Text] [Related]  

  • 2. Determinants of non-response in Helicobacter pylori eradication trials.
    Klotz U; Treiber G; Schwab M
    J Gastroenterol Hepatol; 2005 Sep; 20(9):1471. PubMed ID: 16105147
    [No Abstract]   [Full Text] [Related]  

  • 3. Enantioselective disposition of lansoprazole in relation to CYP2C19 genotypes in the presence of fluvoxamine.
    Miura M; Tada H; Yasui-Furukori N; Uno T; Sugawara K; Tateishi T; Suzuki T
    Br J Clin Pharmacol; 2005 Jul; 60(1):61-8. PubMed ID: 15963095
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetic differences between the enantiomers of lansoprazole and its metabolite, 5-hydroxylansoprazole, in relation to CYP2C19 genotypes.
    Miura M; Tada H; Yasui-Furukori N; Uno T; Sugawara K; Tateishi T; Suzuki T
    Eur J Clin Pharmacol; 2004 Nov; 60(9):623-8. PubMed ID: 15448955
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metabolic disposition of lansoprazole in relation to the S-mephenytoin 4'-hydroxylation phenotype status.
    Sohn DR; Kwon JT; Kim HK; Ishizaki T
    Clin Pharmacol Ther; 1997 May; 61(5):574-82. PubMed ID: 9164419
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of clarithromycin on the enantioselective disposition of lansoprazole in relation to CYP2C19 genotypes.
    Miura M; Tada H; Yasui-Furukori N; Uno T; Sugawara K; Tateishi T; Suzuki T
    Chirality; 2005 Jun; 17(6):338-44. PubMed ID: 15856433
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of high-dose lansoprazole on intragastic pH in subjects who are homozygous extensive metabolizers of cytochrome P4502C19.
    Furuta T; Shirai N; Xiao F; Ohashi K; Ishizaki T
    Clin Pharmacol Ther; 2001 Nov; 70(5):484-92. PubMed ID: 11719736
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enantioselective hydroxylation of omeprazole catalyzed by CYP2C19 in Swedish white subjects.
    Tybring G; Böttiger Y; Widén J; Bertilsson L
    Clin Pharmacol Ther; 1997 Aug; 62(2):129-37. PubMed ID: 9284848
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Metabolic interactions of the proton-pump inhibitors lansoprazole, omeprazole and pantoprazole with other drugs.
    Meyer UA
    Eur J Gastroenterol Hepatol; 1996 Oct; 8 Suppl 1():S21-5. PubMed ID: 8930576
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of clarithromycin on lansoprazole pharmacokinetics between CYP2C19 genotypes.
    Saito M; Yasui-Furukori N; Uno T; Takahata T; Sugawara K; Munakata A; Tateishi T
    Br J Clin Pharmacol; 2005 Mar; 59(3):302-9. PubMed ID: 15752376
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of concomitant dosing of famotidine with lansoprazole on gastric acid secretion in relation to CYP2C19 genotype status.
    Furuta T; Shirai N; Sugimoto M; Nakamura A; Okudaira K; Kajimura M; Hishida A
    Aliment Pharmacol Ther; 2005 Jul; 22(1):67-74. PubMed ID: 15963082
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Cytochrome P450 2C19 genotype -based second line therapy with amoxicillin and lansoprazole after failure of initial helicobacter pylori eradication therapy].
    Asano M; Taniwaki H; Tsuji D; Sato Y; Shimizu T
    Nihon Rinsho; 2005 Dec; 63 Suppl 12():450-3. PubMed ID: 16416832
    [No Abstract]   [Full Text] [Related]  

  • 13. Role of CYP3A4 and CYP2C19 in the stereoselective metabolism of lansoprazole by human liver microsomes.
    Katsuki H; Hamada A; Nakamura C; Arimori K; Nakano M
    Eur J Clin Pharmacol; 2001 Dec; 57(10):709-15. PubMed ID: 11829200
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Theophylline pharmacokinetics are not altered by lansoprazole in CYP2C19 poor metabolizers.
    Ko JW; Jang IJ; Shin JG; Nam SK; Shin SG; Flockhart DA
    Clin Pharmacol Ther; 1999 Jun; 65(6):606-14. PubMed ID: 10391666
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enantioselective disposition of lansoprazole in extensive and poor metabolizers of CYP2C19.
    Kim KA; Shon JH; Park JY; Yoon YR; Kim MJ; Yun DH; Kim MK; Cha IJ; Hyun MH; Shin JG
    Clin Pharmacol Ther; 2002 Jul; 72(1):90-9. PubMed ID: 12152007
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lack of significant effect of grapefruit juice on the pharmacokinetics of lansoprazole and its metabolites in subjects with different CYP2C19 genotypes.
    Uno T; Yasui-Furukori N; Takahata T; Sugawara K; Tateishi T
    J Clin Pharmacol; 2005 Jun; 45(6):690-4. PubMed ID: 15901751
    [No Abstract]   [Full Text] [Related]  

  • 17. Different contribution of CYP2C19 in the in vitro metabolism of three proton pump inhibitors.
    Kita T; Sakaeda T; Baba T; Aoyama N; Kakumoto M; Kurimoto Y; Kawahara Y; Okamura N; Kirita S; Kasuga M; Okumura K
    Biol Pharm Bull; 2003 Mar; 26(3):386-90. PubMed ID: 12612455
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Dosaging of proton pumps inhibitors].
    Brørs O
    Tidsskr Nor Laegeforen; 2006 Sep; 126(18):2397-9. PubMed ID: 16998554
    [No Abstract]   [Full Text] [Related]  

  • 19. [High dose dual PPI/AMPC therapy for the treatment of Helicobacter pylori infection after failure of usual standard triple PPI/AMPC/CAM therapy].
    Shirai N; Furuta T; Sugimoto M; Nakamura A
    Nihon Rinsho; 2005 Nov; 63 Suppl 11():438-41. PubMed ID: 16363575
    [No Abstract]   [Full Text] [Related]  

  • 20. Effects of fluvoxamine on lansoprazole pharmacokinetics in relation to CYP2C19 genotypes.
    Yasui-Furukori N; Saito M; Uno T; Takahata T; Sugawara K; Tateishi T
    J Clin Pharmacol; 2004 Nov; 44(11):1223-9. PubMed ID: 15496639
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.